Pharmaceuticals News and Research

RSS

Esperion, Cleveland Clinic collaborate to research new HDL therapies for cardiovascular disease

Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.

14 Jun 2010

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today presented preclinical and clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor at the 15th Congress of the European Hematology Association in Barcelona, Spain.

14 Jun 2010

Faron, Priaxon enter collaboration to develop new AOC3/SSAO antagonists

Faron Pharmaceuticals Ltd., Turku, Finland and Priaxon AG, Munich, Germany today announced the entry into a collaboration and commercialization agreement to obtain new superior AOC3/SSAO antagonists. This collaboration combines two world-class technologies, the thorough understanding of the AOC3-protein and its ligand interaction with the rapid discovery engine for the development of new chemical inhibitors of protein-protein interactions.

14 Jun 2010

Agile Therapeutics completes $45 million Series B Preferred Stock financing round

Agile Therapeutics, Inc., a late-stage pharmaceutical company specializing in women's healthcare products, today announced that it completed a $45 million Series B Preferred Stock financing. The financing round was co-led by Investor Growth Capital and Care Capital, with strong participation from ProQuest Investments. Kaiser Permanente Ventures and Novitas Capital also joined the financing round. Investor Growth Capital, Care Capital, and Kaiser Permanente Ventures are new investors to Agile.

14 Jun 2010

Oragenics awarded additional $500,000 to further development of MU 1140, DPOLT antibiotics platform

Oragenics, Inc., a biopharmaceutical company, announced today that the National Science Foundation has awarded the Company an additional $500,000 in funds to support the previously awarded SBIR Phase II grant for the Company's DPOLT Lantibiotic Synthesis Platform.

14 Jun 2010

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced the start of a Phase I/II clinical study of TMX-101 for the treatment of Non-Muscle Invasive Bladder Cancer. TMX-101 is an immunotherapeutic compound and Telormedix has already recruited the first patients for this clinical study.

14 Jun 2010

UBC earns high ratings in 2010 late phase market dynamics survey

United BioSource Corporation (UBC) today announced results from an independent survey that examined late phase product development services delivered by 34 contract research organizations and other scientific and medical affairs companies serving the biopharmaceutical industry. The report, titled 2010 Late Phase Market Dynamics and published by Industry Standard Research (ISR), provided data and analysis from a survey that captured information from 149 respondents, representing 95 companies.

14 Jun 2010

New research evaluating substantial disease burden of PNH presented at European Hematology Association

Alexion Pharmaceuticals, Inc. today announced new research evaluating the substantial disease burden of paroxysmal nocturnal hemoglobinuria, an ultra-rare blood disorder, in patients worldwide. The International PNH Registry, involving 580 patients from 99 sites in 14 countries as of May 2010, found that the debilitating symptoms and life-threatening complications of PNH are similar across patient populations around the world.

14 Jun 2010

McDermott's Health Industry Advisory Practice Group recognized as Health Team of the Year

McDermott Will & Emery is pleased to announce the Firm's Health Industry Advisory Practice Group was honored as the "Health Team of the Year" during the Chambers USA Awards in New York on June 10, 2010. This is the first time an award in this category has been given on a national basis by Chambers, and McDermott was selected over four other finalist firms.

14 Jun 2010

Medidata Solutions introduces Grants Manager 3.0 to select correct procedure for budgeting in trial

Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today introduced Medidata Grants Manager 3.0, the newest version of its trial budgeting application in use today by many of the innovative clinical research sponsors in the life sciences industry. Now offered as a web-based solution, Grants Manager 3.0 enables users to build clinical trial grant budgets and benchmark them against Medidata's unique PICAS database of negotiated trial costs without the need to install software.

14 Jun 2010

M&A issues in bio-pharma mega-mergers

The bio-pharma mega-mergers that grabbed headlines last year - Roche + Genentech, Pfizer + Wyeth, and Merck + Schering-Plough - are now in the critical post-integration period and the acquiring companies are finding out how well they planned and executed their integration plans.

14 Jun 2010

TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that TF12, in combination with radiolabeled peptides, produced specific, fast, high-contrast imaging and pretargeted radioimmunotherapy of epithelial cancers that include cancers of the prostate and the ovary.

14 Jun 2010

Chindex, Fosun Pharma form joint venture on manufacturing, distributing medical devices in China

Chindex International, Inc., a leading independent American provider of Western healthcare products and services in the People's Republic of China, and Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a leading manufacturer and distributor of western and Chinese medicine and devices in China, today announced that they have entered into a strategic alliance to utilize respective strengths in China's medical industry.

14 Jun 2010

Chindex International fiscal 2010 net income up 65.3%

Chindex International, Inc., a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced financial results for the fourth quarter and fiscal year ended March 31, 2010.

14 Jun 2010

New bacterial strain could help in long-term cleanup of oil spills

Researchers have discovered a new strain of bacteria that can produce non-toxic, comparatively inexpensive "rhamnolipids," and effectively help degrade polycyclic aromatic hydrocarbons, or PAHs - environmental pollutants that are one of the most harmful aspects of oil spills.

14 Jun 2010

CAMD releases first combined clinical trial data on neuro-degenerative diseases

A new database of more than 4,000 Alzheimer's disease patients who have participated in 11 industry-sponsored clinical trials will be released today by the Coalition Against Major Diseases (CAMD). This is the first database of combined clinical trials to be openly shared by pharmaceutical companies and made available to qualified researchers around the world.

14 Jun 2010

Taro first-quarter net income down 7.8% to $10.2 million

Taro Pharmaceutical Industries Ltd. today provided preliminary, unaudited and unreviewed information on its financial performance for the first quarter of 2010.

14 Jun 2010

USPTO issues patent covering methods for enhancing RNA silencing activity of RNAi agents

Silence Therapeutics plc announces the issuance of United States patent 7,732,593, titled Methods and Compositions For Controlling Efficacy of RNA Silencing, by the United States Patent and Trademark Office. The issued patent, which is based on the seminal research of Phillip D. Zamore, Ph.D., Howard Hughes Medical Institute Investigator, the Gretchen Stone Cook Chair of Biomedical Sciences, and Professor of Biochemistry & Molecular Pharmacology at University of Massachusetts Medical School, generally claims methods of enhancing the RNA silencing activity of RNA interference (RNAi) agents through certain structural modifications.

14 Jun 2010

New report on beneficial effects of nanotechnology innovation on human health, environment

The beneficial effects of nanotechnology innovation on human health and the environment are the focus of a comprehensive report to be presented at the Nano Science and Technology Institute's Nanotech Conference and Expo 2010 in Anaheim, CA, June 21-24, 2010. The report, titled "Nanotechnology, Health and the Environment," was authored by shareholders of the international law firm Greenberg Traurig, LLP; the managing director of Intertox, Inc.,

14 Jun 2010

Nexavar does not meet primary endpoint in Phase 3 NExUS trial for advanced NSCLC

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that the final analysis of the Phase 3 NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar® (sorafenib) tablets in patients with advanced non-squamous non-small cell lung cancer (NSCLC) showed that the study did not meet its primary endpoint of improving overall survival in the first-line setting.

14 Jun 2010

Pharmaceuticals News and Research

Esperion, Cleveland Clinic collaborate to research new HDL therapies for cardiovascular disease

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Faron, Priaxon enter collaboration to develop new AOC3/SSAO antagonists

Agile Therapeutics completes $45 million Series B Preferred Stock financing round

Oragenics awarded additional $500,000 to further development of MU 1140, DPOLT antibiotics platform

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

UBC earns high ratings in 2010 late phase market dynamics survey

New research evaluating substantial disease burden of PNH presented at European Hematology Association

McDermott's Health Industry Advisory Practice Group recognized as Health Team of the Year

Medidata Solutions introduces Grants Manager 3.0 to select correct procedure for budgeting in trial

M&A issues in bio-pharma mega-mergers

TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

Chindex, Fosun Pharma form joint venture on manufacturing, distributing medical devices in China

Chindex International fiscal 2010 net income up 65.3%

New bacterial strain could help in long-term cleanup of oil spills

CAMD releases first combined clinical trial data on neuro-degenerative diseases

Taro first-quarter net income down 7.8% to $10.2 million

USPTO issues patent covering methods for enhancing RNA silencing activity of RNAi agents

New report on beneficial effects of nanotechnology innovation on human health, environment

Nexavar does not meet primary endpoint in Phase 3 NExUS trial for advanced NSCLC

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence